Join to View Full Profile
55 Fruit StBoston, MA 02114
Phone+1 617-726-6500
Fax+1 617-724-1079
Dr. Juric is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2009 - 2012
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2007 - 2009
University of Zagreb Faculty of MedicineClass of 2001
Certifications & Licensure
MA State Medical License 2011 - 2025
American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Start of enrollment: 2012 Mar 01
- Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer Start of enrollment: 2012 Sep 21
- BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
- Join now to see all
Publications & Presentations
PubMed
- Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets.Vindhya Vijay, Negin Karisani, Lei Shi, Yu-Han Hung, Phuong Vu
Cancer Discovery. 2025-09-04 - Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer.Erika Hamilton, Timothy Pluard, Judy S Wang, Aki Morikawa, Stephen Johnston
Breast Cancer Research. 2025-08-19 - 3 citationsOverall Survival with Inavolisib in-Mutated Advanced Breast Cancer.Komal L Jhaveri, Seock-Ah Im, Cristina Saura, Sibylle Loibl, Kevin Kalinsky
The New England Journal of Medicine. 2025-07-10
Press Mentions
New Drug Combination Increases Overall Survival in Patients with PIK3CA-Mutated Advanced Breast CancerJune 2nd, 2025- Well-Designed Phase Ia and Ib Trials Point the Way to New Treatment OptionsMarch 5th, 2025
- Evaluating Inavolisib vs Alpelisib plus Fulvestrant for Hormone Receptor-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast CancerSeptember 24th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
